Janux Therapeutics, Inc. (JANX) shares rallied 8.8% in the last trading session to close at $29.76. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 15.4% gain over the past four weeks.
The price rise can be attributed to growing investor confidence in the company’s pipeline. The most advanced candidates in Janux’s pipeline are JANX007 and JANX008, which are being evaluated in early-stage clinical studies for prostate cancer and solid tumors, respectively. Updates on JANX007 and JANX008 are expected in the second half of 2025.
This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -17.7%. Revenues are expected to be $7.81 million, up 1675.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Janux Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on JANX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Janux Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Entrada Therapeutics, Inc. (TRDA), finished the last trading session 0.6% higher at $7.35. TRDA has returned 25.2% over the past month.
For Entrada Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.04. This represents a change of -197.1% from what the company reported a year ago. Entrada Therapeutics currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Janux Therapeutics, Inc. (JANX): Free Stock Analysis Report Entrada Therapeutics, Inc. (TRDA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
